OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:07 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

The Use of Teledermatology in the Treatment of Patients With Severe Acne on Isotretinoin

NCT03707236 · Massachusetts General Hospital · NA · withdrawn · last registry update 2023-04-06 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Study was planned prior to COVID-19; after pandemic teledermatology use became prevalent making the results of this study no longer necessary/relevant”–Registry record, Massachusetts General Hospital

Also happening at the time. Not shown to be a cause.

No drug target was found for this trial's interventions, so there is no same-target timeline.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision